Caffeine Clinical Trial
Official title:
Can Coffee/Caffeine Improve Post-Operative Gastrointestinal Recovery? A Vanguard Randomized Controlled Trial
Verified date | January 2024 |
Source | Sunnybrook Health Sciences Centre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Disruption of the normal gastrointestinal (GI) motility is a well-known consequence of major surgery. The pathophysiology behind this phenomenon is not fully understood but involves the autonomic nervous system as well as a systemic stress response to surgery. A number of factors interfere with GI motor activity, such as the direct manipulation of intestines during surgery and the use of opioid analgesia. Post-operative ileus (POI) refers to a delay in regaining GI motility beyond the anticipated normal duration of time. Signs and symptoms include nausea, vomiting, abdominal distention, the absence of flatus or stool in the preceding 24 hours, and/or an inability to tolerate oral intake. The incidence of POI in abdominal surgery is estimated to be approximately 10%-30%. Beyond increased patient discomfort and distress, the development of POI is associated with increased healthcare costs. Coffee is a popular beverage: two thirds of Canadians are coffee drinkers, averaging approximately 3.2 cups per day. Coffee is composed of hundreds of chemicals, many with demonstrated pharmacologic effects. The most well-known of these compounds is caffeine, known to exert a stimulatory effect on the cardiovascular and nervous system. A recent systematic review of 7 randomized controlled trials (N=606 colorectal and gynecology surgical patients) determined that the consumption of coffee reduced the time of several measures of GI recovery, such as time to tolerance of food, without any increased rate of complications or adverse events although overall, the evidence was graded as low to moderate certainty, and further confirmatory studies are needed. In this trial, patients aged 18 years or higher who undergo laparoscopic or open abdominal surgery, with an estimated length of stay > 24 hours will be randomized to receive approximately one cup of either coffee, decaffeinated coffee, or warm water, three times daily. This trial will be conducted under the IMPACTS (Innovative, Multicentre, Patient-centred Approach to Clinical Trials in Surgery) program umbrella and will follow IMPACTS methodology. For the Vanguard trial, the aim is to determine the feasibility of conducting a definitive trial. Future outcomes of interest include: time to first flatus, time to first bowel movement, placement of an NG tube, length of stay in hospital, 30-day mortality, and 30-day postoperative complications.
Status | Active, not recruiting |
Enrollment | 174 |
Est. completion date | April 1, 2024 |
Est. primary completion date | October 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Planned elective laparoscopic or open abdominal surgery - Patient is scheduled to remain in hospital for at least one night, post-operatively Exclusion Criteria: - Known intolerance to coffee or caffeine - Unwilling to stop current caffeine consumption (coffee or tea) during trial |
Country | Name | City | State |
---|---|---|---|
Canada | North York General Hospital | North York | Ontario |
Canada | The Ottawa Hospital | Ottawa | Ontario |
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Sunnybrook Health Sciences Centre |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of accrual | Average number of patients enrolled per month across the 3 sites for the trial: feasible if 10 or more | 1 year | |
Primary | Ability to deliver intervention patient is randomized to receive | Feasible if > 90% of patients receive the correct intervention | 1 year | |
Primary | Ability to collect complete data for patient-reported outcomes | Feasible if > 80% of data is collected | 1 year | |
Primary | Ability to link data from patient-reported outcome measures with Institute for Clinical/Evaluative Sciences and National Surgical Quality Improvement Program datasets | Feasible if linkage is possible in > 90% of patients | 1 year | |
Primary | Measurement of baseline data | Median number of hours until flatus in control group
Median number of hours until flatus in coffee and decaffeinated coffee groups |
1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06038903 -
The Turkish Version Of The Brief-Caffeine Expectancy Questionnaire
|
||
Completed |
NCT02900261 -
Study on Sodium and Caffeine in Children and Adolescents
|
||
Completed |
NCT03850275 -
The Effects of e+Shots Energy Beverage on Mental Energy
|
N/A | |
Completed |
NCT01924481 -
Effects of a Cocoa Shot on the Human Brain
|
N/A | |
Completed |
NCT01330680 -
Genetic Determinants of Cardiovascular Response to Coffee Drinking
|
N/A | |
Completed |
NCT00184912 -
The Effect of Caffeine on Ischemic Preconditioning
|
N/A | |
Completed |
NCT03859882 -
Protocol PERCAF 2018
|
N/A | |
Completed |
NCT02832401 -
The Impact of Caffeine on Cognition in Schizophrenia
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Recruiting |
NCT05503732 -
Effects of Energy Drinks on Sleep and Cardiovascular Health
|
N/A | |
Not yet recruiting |
NCT05521386 -
The Effects of Caffeine on Heart Rate and Heart Rate Variability
|
N/A | |
Completed |
NCT06039358 -
Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects
|
N/A | |
Completed |
NCT05559372 -
Energy Drink Effects on Performance, Mood, and Cardiovascular Outcomes
|
N/A | |
Completed |
NCT01783561 -
Early Versus Routine Caffeine Administration in Extremely Preterm Neonates
|
Phase 4 | |
Completed |
NCT04852315 -
Acute Caffeine Ingestion on Futsal Performance
|
N/A | |
Completed |
NCT05975489 -
Genetics in the Effect of Caffeine on Fat Oxidation
|
N/A | |
Recruiting |
NCT03298347 -
Caffeine for Preterm Infants With Apnea of Prematurity(AOP)
|
N/A | |
Completed |
NCT01435486 -
Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants
|
N/A | |
Completed |
NCT04869176 -
Effect of Caffeine on Heart Rate Variability in Newborns
|
N/A | |
Completed |
NCT04585854 -
Effect of Caffeine on Myocardial Oxygenation
|
N/A |